Recombinant Antigen Production Platform
Four Expression Systems
E.coli, yeast, insect cells (SF-α), and HEK293 human cells.
Tailored for Antigen Complexity
From simple bacterial expression to fully human-like post-translational modifications.
End-to-End R&D Process
Antigen design ➡ vector construction ➡ expression ➡ purification ➡ QC.
Advanced Purification & Analytics
Affinity, ion exchange, gel filtration, HPLC, MS, ELISA, and more.
High Purity & Bioactivity
Suitable for research, diagnostics, and clinical applications.
GMP-Ready Quality Standards
Production aligned with regulatory and clinical-grade requirements.
Multi-System Expression Capability
-
E. coli for cost-effective, high-yield production of simple antigens.
-
Yeast for antigens requiring glycosylation and enhanced immunogenicity.
-
Insect cells (SF-α) for complex proteins with precise folding and post-translational modifications.
-
HEK293 for human-like post-translational modifications and high-fidelity antigen structure.
Integrated R&D and Manufacturing Process
From antigen design and gene optimization to vector construction, cell culture, expression, purification, and quality evaluation, every step follows standardized workflows. Advanced purification techniques (affinity, ion exchange, gel filtration) and analytical methods (HPLC, MS, SDS-PAGE, ELISA) ensure high purity, bioactivity, and batch consistency.
Strict Quality Control
All antigens undergo comprehensive testing for purity, structural integrity, immunogenicity, and bioactivity. This rigorous process guarantees that the recombinant antigens meet the demanding requirements of immune cell research and therapeutic development.
